Coexisting systemic lupus erythematosus and sickle cell disease: A diagnostic and therapeutic challenge

Journal of Clinical Rheumatology

Volumn 11, Issue 2, 2005, Pages 86-92

  Khalidi, Nader A ^a   Ajmani, Harpinder ^b   Varga, John ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Multisystem involvement; Sickle cell disease; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; GLUCOCORTICOID; HEMOGLOBIN S; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; HEMOGLOBIN SS; HEMOGLOBINOPATHY; HEMOLYSIS; HUMAN; KIDNEY BIOPSY; MALE; PREVALENCE; PRIORITY JOURNAL; RARE DISEASE; SICKLE CELL ANEMIA; SPLEEN FUNCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE;

EID: 17744367421     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000158549.92844.96     Document Type: Article

References (70)

1. Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of prevalence of selected arthritis and musculoskeletal diseases in the United States. J Rheumatol 1989;16:427-441.
2. Hochberg MC. Systemic lupus erythematosus. Rheum Dis Clin North Am. 1990;16:640-671.
3. Siegel M, Lee SL. The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum. 1973:1-54.
4. Fessel WJ. Systemic lupus erythematosus in the community. Incidence, prevalence, outcome and first symptoms; the highest prevalence in black women. Arch Intern Med. 1974;134:1027-1035.
5. Lahita RG. Special report: adjusted lupus prevalence. Results of a marketing study by the Lupus Foundation of America. Lupus. 1995;4: 450-453.
6. Hochberg MC, Perlmutter DL, Medsger TA, et al. Prevalence of self reported physician-diagnosed systemic lupus erythematosus in the USA. Lupus. 1995;4:454-456.
7. Sickle Cell Disease Guideline Panel. Sickle Cell Disease: Screening, Diagnosis, Management and Counseling in Newborns and Infants, Clinical Practice Guideline, no. 6. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993.
8. Office of Health Promotion. Information on Sickle Cell Disease. Springfield, IL: Illinois Dept of Public Health; 1999.
9. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-1644.
10. Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2002;16:847-858.
11. Wilson WA, Nicholson GD, Hughes GR, et al. Systemic lupus erythematosus and sickle-cell anemia. BMJ. 1976;1:813.
12. Karthikeyan G, Wallace SL, Blum L. SLE and sickle cell disease. Arthritis Rheum. 1978;21:862-863.
13. White LE, Reeves JD. Polyarthritis and positive LE preparation in sickle hemoglobinopathies: a report of two cases. J Pediatr. 1979;95:1003-1004.
14. Luban NL, Boeckx RL, Barr O. Sickle cell anemia and SLE. J Pediatr. 1980;96:1120.
15. Shaw HE Jr, Osher RH, Smith JL. Amaurosis Fugax associated with SC hemoglobinopathy and lupus erythematosus. Am J Ophthalmol. 1979; 87:281-285.
16. Warrier RP, Sahney S, Walker H. Hemoglobin sickle cell disease and systemic lupus erythematosus. J Natl Med Assoc. 1984;76:1030-1031.
17. Katsanis E, Hsu E, Koon-Hung L, et al. Systemic lupus erythematosus and sickle hemoglobinopathies: a report of two cases and review of the literature. Am J Hematol. 1987;25:211-214.
18. Eissa MM, Lawrence JM III, McKenzie L, et al. Systemic lupus erythematosus in a child with sickle cell disease. South Med J. 1995; 88:1176-1178.
19. Pham PT, Lew SQ, Balow JE. Sickle cell nephropathy during the postpartum period in a patient with SLE. Am J Kidney Dis. 1997;30: 879-883.
20. Shetty AK, Baliga MR, Gedalia A, et al. Systemic lupus erythematosus and sickle cell disease. Indian J Pediatr. 1988;65:618-621.
21. Saxena VR, Mina R, Moallem HJ, et al. Systemic lupus erythematosus in children with sickle cell disease. J Pediatr Hematol Oncol. 2003;25: 668-671.
22. Shapiro MP, Hayes JA. Fat embolism in sickle cell disease: a report of a case with brief review of the literature. Arch Intern Med. 1984;144: 181-182.
23. Shetty AK, Kumar R, Gedalia A, et al. Sickle cell anemia with systemic lupus erythematosus: response to hydroxyurea therapy. J Pediatr Hematol Oncol. 1998;20:335-337.
24. Abialmouona J, Shoemaker DW, Pullicino PM, et al. Marked cerebrospinal pleocytosis in systemic lupus erythematosus related to cerebral ischemia. J Rheumatol. 1992;19:626-629.
25. Hochberg MC. Updating the American College of Rheumatology criteria for the classification of systemic lupus erythematosus [Letter]. Arthritis Rheum. 1997;40:1725.
26. Baethge BA, Bordelon TR, Mills GM, et al. Antinuclear antibodies in sickle cell disease. Acta Hematol. 1990;84:186-189.
27. Quisomoro FP, Johnson C. Serum autoantibodies in patients with sickle cell anemia. Am J Med Sci. 1984;287:13-15.
28. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory responses in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411-420.
29. Johnston RB Jr, Newman SL, Struth AG. An abnormality of the alternative pathway of complement activation in sickle-cell disease. N Engl J Med. 1973;288:803-808.
30. Koethe SM, Casper JT, Rodey GE. Alternative complement pathway activity in sera from patients with sickle cell disease. Clin Exp Immunol. 1976:56-60.
31. Corry JM, Polhill RB, Edmonds SR, et al. Activity of the alternative complement pathway after splenectomy: comparison to activity in sickle cell disease and hypogammaglobulinemia. J Pediatr. 1979;95: 964-969.
32. Wilson WA, Deceulaer K, Morgan AG. Sickle cell anemia, complement and systemic lupus erythematosus. Arthritis Rheum: 1979;22:803.
33. Ricker DM, Hebert LA, Rohde R, et al. Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 1991;18:678-685.
34. Houssian FA, D'Crue D, Vienna J, et al. Lupus nephritis: the significance of serological tests at the time of biopsy. Clin Exp Rheumatol. 1991;9:345-349.
35. Zonana-Nacach A, Salar M, Sanchez ML, et al. Measurement of clinical activity of systemic lupus erythematosus and laboratory abnormalities: a 12-month prospective study. J Rheumatol. 1995;22:45-49.
36. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325:1476-1481.
37. Petri M. Treatment of systemic lupus erythematosus: an update. Am Fam Physician. 1998;2753-2762.
38. Schumacher HR, Andrews R, McLaughlin G. Arthropathy in sickle-cell disease. Ann Intern Med. 1973;78:203-211.
39. Espinoza LR, Spilberg I, Osterland CK. Joint manifestations of sickle cell disease. Medicine: 1974;53:295-305.
40. Mann D, Schumacher HR Jr. Pseudoseptic inflammatory knee effusion caused by phagocytosis of sickled erythrocytes after fracture into the knee joint. Arthritis Rheum. 1995;38:284-287.
41. Schumacher HR Jr, Howe HS. Synovial fluid cells in systemic lupus erythematosus: light and electron microscopic studies. Lupus. 1995;4: 353-364.
42. Natour J, Montezzo LC, Moura LA, et al. A study of synovial membrane of patients with systemic lupus erythematosus (SLE). Clin Exp Rheumatol. 1991;9:221-225.
43. Mankad VN, Williams JP, Harpen MD, et al. Magnetic resonance imaging in sickle cell disease: clinical, hematologic and pathologic correlations. Blood. 1990;75:274-283.
44. Schumacher HR Jr, Van Linthoudt DV, Manno CS, et al. Diffuse chondrolytic arthritis in sickle cell disease. J Rheumatol. 1993;20:385-389. (Deleted in proof).
45. Timsit MA, Bardin T. Metabolic arthropathies. Curr Opin Rheumatol. 1994;6:448-453. (Deleted in proof).
46. Ohene-Frempong K, Wiener SJ, Sleeper LA, et al., and the Cooperative Study of Sickle Cell Disease. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288-294.
47. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599-608.
48. West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am. 1994;20: 129-158.
49. Newelt CM, Lacks S, Kaye BR, et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med. 1995;98:32-41.
50. Schneebaum AB, Singleton JD, West SG, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med. 1991;90:54-62.
51. Tzioufas AG, Tzortzakis, Panou-Pomonis E, et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis. 2000;59:99-104.
52. Kugler S, Anderson B, Cross D, et al. Abnormal cranial magnetic resonance imaging scans in sickle cell disease. Neurological correlates and clinical implications. Arch Neurol. 1993;50:629-635.
53. Lane PA. Sickle cell disease. Pediatr Clin North Am. 1996;43:639-664.
54. Sibbitt WL, Sibbitt RR, Brooks WM. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1999;42:2026-2038.
55. Powars DR. Management of cerebral vasculopathy in children with sickle cell anemia. Br J Haematol. 2000;108:666-678.
56. Russell MO, Goldberg HI, Hodson A, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood. 1984;63:162.
57. Wang WC, Kovnar EH, Tonkin IL, et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr. 1991;118:377.
58. Craft S, Schatz J, Glauser TA, et al. Neuropsychologic effects of stroke in children with sickle cell disease. J Pediatr. 1993;123:712-717.
59. Adams RJ. Stroke prevention in sickle cell disease. Curr Opin Hematol. 2000;7:101-105.
60. Koshy M, Chinnamma T, Goodwin J. Vascular lesions in the central nervous system in sickle cell disease (neuropathology). J Assoc Acad Minor Phys. 1990;1:71-78. (Deleted in proof).
61. Hanly JG, Walsh NMG, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992;19:732-741. (Deleted in proof).
62. Bakir A, Hathiwala SC, Ainis H, et al. Prognosis of the nephrotic syndrome in sickle glomerulopathy. Am J Nephrol. 1987;7:110-115.
63. Iskandar SS, Morgann RG, Browning MC, et al. Membranoproliferative glomerulonephritis associated with sickle cell disease in two siblings. Clin Nephrol. 1991;35:47-51.
64. Pistiner M, Wallace DJ, Nessim S, et al. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum. 1991;2155-2164.
65. Nossent HC, Henzen-Logmans SC, Vroom TM, et al. Contribution of renal biopsy data in predicting outcome in lupus nephritis: analysis of 116 patients. Arthritis Rheum. 1990;33:970-977.
66. McLaughlin J, Gladman DD, Urowitz MB, et al. Kidney biopsy in systemic lupus erythematosus. II. Survival analysis according to biopsy results. Arthritis Rheum. 1991;34:1268-1273.
67. Garcia Tello A, Villegas Martinez A, Gonzalez Fernandez AF. Hematological abnormalities in patients with systemic lupus erythematosus. An Med Interna. 2002;19:539-543.
68. Nossent JC, Swaak AJ. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med. 1991;80:605-612.
69. Keeling DM, Isenberg DA. Haematological manifestations of systemic lupus erythematosus. Blood Rev. 1993;7:199-207.
70. Voulgarelis M, Kokori SI, Ioannidis JP, et al. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin. Ann Rheum Dis. 2000;59:217-222.